Preprint Article Version 1 This version is not peer-reviewed

Current Management of Extensive Stage Small Cell Lung Cancer in Italy: A National Survey on Behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Alessio Bruni
,
Vieri Scotti
,
Maria Alessia Zerella
* ,
Federica Bertolini
,
Jessica Imbrescia
,
Emanuela Olmetto
,
Chiara Bennati
,
Francesco Cuccia
,
Marianna Miele
,
Niccolò Giaj-Levra
,
Marcello Tiseo
,
Patrizia Ciammella
,
Stefano Vagge
,
Marco Galaverni
,
Antonio Pontoriero
,
Serena Badellino
,
Ruggero Spoto
,
Emanuele Alì
,
Paolo Borghetti
Version 1 : Received: 27 September 2024 / Approved: 27 September 2024 / Online: 27 September 2024 (11:12:43 CEST)

How to cite: Bruni, A.; Scotti, V.; Zerella, M. A.; Bertolini, F.; Imbrescia, J.; Olmetto, E.; Bennati, C.; Cuccia, F.; Miele, M.; Giaj-Levra, N.; Tiseo, M.; Ciammella, P.; Vagge, S.; Galaverni, M.; Pontoriero, A.; Badellino, S.; Spoto, R.; Alì, E.; Borghetti, P. Current Management of Extensive Stage Small Cell Lung Cancer in Italy: A National Survey on Behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Preprints 2024, 2024092202. https://doi.org/10.20944/preprints202409.2202.v1 Bruni, A.; Scotti, V.; Zerella, M. A.; Bertolini, F.; Imbrescia, J.; Olmetto, E.; Bennati, C.; Cuccia, F.; Miele, M.; Giaj-Levra, N.; Tiseo, M.; Ciammella, P.; Vagge, S.; Galaverni, M.; Pontoriero, A.; Badellino, S.; Spoto, R.; Alì, E.; Borghetti, P. Current Management of Extensive Stage Small Cell Lung Cancer in Italy: A National Survey on Behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Preprints 2024, 2024092202. https://doi.org/10.20944/preprints202409.2202.v1

Abstract

Background: Extensive-stage SCLC (ES-SCLC) treatment has recently been revolutionized by the advent of immune checkpoint inhibitors. This survey was conducted to evaluate the current pattern of care among Italian clinicians, in particular about the integration with radiation therapy (RT). Methods: In June 2023, 225 Italian cancer care professionals were invited to 21-question web-based survey about the ES-SCLC management through personal contacts and the Italian Association for Radiotherapy and Clinical Oncology (AIRO) network. Results: We received 90 responses, the majority were radiation oncologists (89%) with more than 10 years of experience (51%). Preferred management of ES-SCLC in patients with a good performance status was concomitant chemo-immunotherapy (84%). Almost all respondents recommended prophylactic cranial irradiation (PCI) (85%), taking into account age and thoracic response; PCI was performed mainly between the end of chemotherapy before starting immunotherapy (37%), with three-dimensional conformal technique (46%). Furthermore, 83% of respondents choose to deliver thoracic RT in case of both intrathoracic and extrathoracic response with a RT schedule of 30 Gy/10 fractions. Stereotactic RT is increasingly being used in oligoprogressions. Conclusions: Our analysis showed the variability of real-world management of ES-SCLC. Future clinical trials and developments are needed to improve the multidisciplinary treatment of these patients.

Keywords

radiation therapy; small cell lung cancer; national Italian survey

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.